Coeptis Therapeutics Holdings Inc
COEP14.640USD
-0.110-0.75%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
61.00MMarket Cap
LossP/E TTM
More Details of Coeptis Therapeutics Holdings Inc Company
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.
Coeptis Therapeutics Holdings Inc Info
Ticker SymbolCOEP
Company nameCoeptis Therapeutics Holdings Inc
IPO dateDec 17, 2020
CEO- -
Number of employees5
Security typeOrdinary Share
Fiscal year-endDec 17
Address105 Bradford Road, Suite 420
CityWEXFORD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code15090
Phone17249346467
Websitehttps://coeptistx.com/
Ticker SymbolCOEP
IPO dateDec 17, 2020
CEO- -
Company Executives of Coeptis Therapeutics Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Dr. Tara Maria Desilva, Ph.D.
Dr. Tara Maria Desilva, Ph.D.
Independent Director
Independent Director
--
--
Mr. Brian Cogley
Mr. Brian Cogley
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Mr. David Mehalick
Mr. David Mehalick
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
130.07K
--
Ms. Christine Sheehy
Ms. Christine Sheehy
Vice President - Compliance, Secretary
Vice President - Compliance, Secretary
50.53K
--
Mr. Daniel (Dan) Yerace
Mr. Daniel (Dan) Yerace
Vice President - Operations, Director
Vice President - Operations, Director
45.53K
--
Mr. Christopher Calise
Mr. Christopher Calise
Independent Director
Independent Director
--
--
Mr. Christopher Cochran
Mr. Christopher Cochran
Independent Director
Independent Director
--
--
Mr. Philippe Deschamps
Mr. Philippe Deschamps
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Nov 2
Updated: Sun, Nov 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Other
86.86%
Shareholders
Shareholders
Proportion
Calise (Chris)
6.49%
Mehalick (David)
2.70%
Armistice Capital LLC
1.97%
Sheehy (Christine Elise)
1.05%
Yerace (Daniel Alexander)
0.94%
Other
86.86%
Shareholder Types
Shareholders
Proportion
Individual Investor
11.27%
Corporation
2.13%
Hedge Fund
1.97%
Investment Advisor
0.64%
Investment Advisor/Hedge Fund
0.42%
Other
83.58%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
31
146.21K
3.03%
+12.13K
2025Q2
42
850.21K
24.20%
+80.97K
2025Q1
44
802.79K
23.54%
+88.77K
2024Q4
46
470.87K
21.82%
-146.34K
2024Q3
60
665.36K
32.36%
-151.44K
2024Q2
63
660.64K
38.75%
-415.23K
2024Q1
86
813.98K
47.41%
-385.62K
2023Q4
86
964.24K
63.23%
-125.48K
2023Q3
87
697.73K
55.24%
-487.79K
2023Q2
87
705.35K
60.53%
-350.78K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Calise (Chris)
312.69K
6.49%
--
--
Sep 11, 2025
Mehalick (David)
130.07K
2.7%
--
--
Sep 11, 2025
Armistice Capital LLC
94.77K
1.97%
+94.77K
--
Sep 30, 2024
Sheehy (Christine Elise)
50.53K
1.05%
--
--
Sep 11, 2025
Yerace (Daniel Alexander)
45.53K
0.94%
-5.00K
-9.89%
Sep 11, 2025
The Vanguard Group, Inc.
27.53K
0.57%
+3.09K
+12.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
20.28K
0.42%
+311.00
+1.56%
Jun 30, 2025
Salkind (Gene)
4.21K
0.09%
--
--
Sep 11, 2025
Sea Otter Advisors LLC
2.25K
0.05%
--
--
Jun 30, 2024
Steward Partners Investment Advisory, LLC
1.00K
0.02%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Date
Type
Ratio
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
Dec 27, 2024
Merger
20→1
